Vertex Pharmaceuticals SG&A increased by 9.4% to $487.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 29.0%, from $377.60M to $487.00M. Over 4 years (FY 2021 to FY 2025), SG&A shows an upward trend with a 20.2% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryEfficiency
SignalLower is better
VolatilityStable
First reportedQ4 2013
Last reportedQ4 2025
How to read this metric
Increases may indicate aggressive marketing or expansion, while decreases often reflect cost-cutting measures or improved corporate efficiency.
Detailed definition
The sum of all direct and indirect selling expenses and all general and administrative expenses of a company. This inclu...
Peer comparison
Used to assess the 'leaness' of a company's corporate structure relative to its peers.
Metric ID:
is_selling_general_and_administrativeHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $194.67M | $198.19M | $255.17M | $215.20M | $215.30M | $246.80M | $267.40M | $241.10M | $262.60M | $263.80M | $369.10M | $342.70M | $372.20M | $371.80M | $377.60M | $396.40M | $424.60M | $445.10M | $487.00M |
| QoQ Change | — | +1.8% | +28.7% | -15.7% | +0.0% | +14.6% | +8.3% | -9.8% | +8.9% | +0.5% | +39.9% | -7.2% | +8.6% | -0.1% | +1.6% | +5.0% | +7.1% | +4.8% | +9.4% |
| YoY Change | — | — | — | — | +10.6% | +24.5% | +4.8% | +12.0% | +22.0% | +6.9% | +38.0% | +42.1% | +41.7% | +40.9% | +2.3% | +15.7% | +14.1% | +19.7% | +29.0% |
Range$194.67M – $487.00M
CAGR+22.6%
Avg YoY Growth+21.6%
Median YoY Growth+19.7%
Current Streak5 quarters growth
SG&A at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's sg&a?
- Vertex Pharmaceuticals (VRTX) reported sg&a of $487.00M in Q4 2025.
- How has Vertex Pharmaceuticals's sg&a changed year-over-year?
- Vertex Pharmaceuticals's sg&a increased by 29.0% year-over-year, from $377.60M to $487.00M.
- What is the long-term trend for Vertex Pharmaceuticals's sg&a?
- Over 4 years (2021 to 2025), Vertex Pharmaceuticals's sg&a has grown at a 20.2% compound annual growth rate (CAGR), from $840.10M to $1.75B.
- What does sg&a mean?
- The day-to-day costs of running the business and marketing its products.